Abstract:Objective To evaluate the efficacy and safety of Moses holmium laser resection of bladder tumor for non-muscle-invasive bladder cancer.Methods From March 2018 to August 2019, 61 cases with non muscle invasive bladder cancer treated in xuzhou cancer hospital and Secondary hospital of Dalian medical university were assigned to receive re-transurethral resection of bladder tumor. All the cases were divided into Moses group (n = 35) and TURBT group (n = 26). The operation time, dewelling catheter time, bladder irrigation time, the incidence of obturator reflex, the accuracy of pathology, and the recurrence rate in the follow-up period were compared between the two groups, and the data were statistically analyzed.Results All the cases were successfully undergone operation. There was significant difference in the incidence of obturator nerve reflex between the two groups (P < 0.05). There was no significant difference in the operation time, dewelling catheter time, bladder irrigation time in the two groups (P > 0.05). There were 33 cases in Moses group and 10 cases in TURBT group meet the requirement of pathological staging. The difference in pathological diagnosis accuracy was statistically significant between the two groups (P < 0.05). All patients were followed up for 3 to 14 months, with an average of (10.0±2.4) months. The tumor recurrence was found in 3 cases in Moses group (8.6%, 3/35) and 2 cases in the TURBT group (7.7%, 2/26). There was no significant difference (P >0.05).Conclusion Moses holmium laser transurethral resection of bladder tumor is a safe and effective therapeutic method for non-muscle-invasive bladder cancer, which meet the needs of postoperative pathological diagnosis.